41 related articles for article (PubMed ID: 10617694)
1. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
Schuetz EG; Umbenhauer DR; Yasuda K; Brimer C; Nguyen L; Relling MV; Schuetz JD; Schinkel AH
Mol Pharmacol; 2000 Jan; 57(1):188-97. PubMed ID: 10617694
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy.
Graziani M; Nisticò R
Front Pharmacol; 2015; 6():122. PubMed ID: 26106330
[TBL] [Abstract][Full Text] [Related]
3. Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep (-/-) mice.
Hrycay E; Forrest D; Liu L; Wang R; Tai J; Deo A; Ling V; Bandiera S
Mol Cell Biochem; 2014 Apr; 389(1-2):119-32. PubMed ID: 24399466
[TBL] [Abstract][Full Text] [Related]
4. Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.
Lacher SE; Gremaud JN; Skagen K; Steed E; Dalton R; Sugden KD; Cardozo-Pelaez F; Sherwin CM; Woodahl EL
J Pharmacol Exp Ther; 2014 Feb; 348(2):336-45. PubMed ID: 24297779
[TBL] [Abstract][Full Text] [Related]
5. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.
Choi YH; Yu AM
Curr Pharm Des; 2014; 20(5):793-807. PubMed ID: 23688078
[TBL] [Abstract][Full Text] [Related]
6. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2011 Dec; 92(12):1342-7. PubMed ID: 22094953
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein dysfunction contributes to hepatic steatosis and obesity in mice.
Foucaud-Vignault M; Soayfane Z; Ménez C; Bertrand-Michel J; Martin PG; Guillou H; Collet X; Lespine A
PLoS One; 2011; 6(9):e23614. PubMed ID: 21949682
[TBL] [Abstract][Full Text] [Related]
8. (±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice.
Scheidweiler KB; Ladenheim B; Barnes AJ; Cadet JL; Huestis MA
J Anal Toxicol; 2011 Sep; 35(7):470-80. PubMed ID: 21871156
[TBL] [Abstract][Full Text] [Related]
9. Using evolutionary demography to link life history theory, quantitative genetics and population ecology.
Coulson T; Tuljapurkar S; Childs DZ
J Anim Ecol; 2010 Nov; 79(6):1226-40. PubMed ID: 20704627
[TBL] [Abstract][Full Text] [Related]
10. Update information on drug metabolism systems--2009, part I.
Guengerich FP; Rendic S
Curr Drug Metab; 2010 Jan; 11(1):1-3. PubMed ID: 20307256
[TBL] [Abstract][Full Text] [Related]
11. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow.
Ghosh C; Gonzalez-Martinez J; Hossain M; Cucullo L; Fazio V; Janigro D; Marchi N
Epilepsia; 2010 Aug; 51(8):1408-17. PubMed ID: 20074231
[TBL] [Abstract][Full Text] [Related]
12. Genetic predictors of interindividual variability in hepatic CYP3A4 expression.
Lamba V; Panetta JC; Strom S; Schuetz EG
J Pharmacol Exp Ther; 2010 Mar; 332(3):1088-99. PubMed ID: 19934400
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the disposition of chiral polychlorinated biphenyls in female mdr 1a/b knockout versus wild-type mice using multivariate analyses.
Milanowski B; Lulek J; Lehmler HJ; Kania-Korwel I
Environ Int; 2010 Nov; 36(8):884-92. PubMed ID: 19923000
[TBL] [Abstract][Full Text] [Related]
14. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits.
Fang HM; Xu JM; Mei Q; Diao L; Chen ML; Jin J; Xu XH
Acta Pharmacol Sin; 2009 Nov; 30(11):1566-72. PubMed ID: 19820718
[TBL] [Abstract][Full Text] [Related]
15. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.
Beumer JH; Franke NE; Tolboom R; Buckle T; Rosing H; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Invest New Drugs; 2010 Apr; 28(2):145-55. PubMed ID: 19238326
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.
Pereira de Oliveira M; Garcion E; Venisse N; Benoit JP; Couet W; Olivier JC
Pharm Res; 2005 Nov; 22(11):1898-1905. PubMed ID: 16132350
[TBL] [Abstract][Full Text] [Related]
18. The MDR1 (ABCB1) gene polymorphism and its clinical implications.
Ieiri I; Takane H; Otsubo K
Clin Pharmacokinet; 2004; 43(9):553-76. PubMed ID: 15217301
[TBL] [Abstract][Full Text] [Related]
19. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Collett A; Tanianis-Hughes J; Hallifax D; Warhurst G
Pharm Res; 2004 May; 21(5):819-26. PubMed ID: 15180340
[TBL] [Abstract][Full Text] [Related]
20. The complexities of hepatic drug transport: current knowledge and emerging concepts.
Chandra P; Brouwer KL
Pharm Res; 2004 May; 21(5):719-35. PubMed ID: 15180326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
